Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion.
## Primary Indications
* Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD).
* Maintenance of healing of erosive esophagitis.
* Treatment of pathological hypersecretory conditions, such as Zollinger-Ellison syndrome.
## Adult Dosing
* **Erosive Esophagitis (Healing):** 40 mg orally or intravenously once daily for up to 8 weeks.
* **Erosive Esophagitis (Maintenance):** 40 mg orally once daily. May consider 20 mg orally once daily in some patients.
* **Pathological Hypersecretory Conditions:** Starting dose is typically 40 mg orally or intravenously twice daily. Doses may be titrated upwards as clinically indicated. Doses as high as 240 mg daily have been administered intravenously.
## Pediatric Dosing
Dosing varies by indication and age. Specific recommendations are:
* **GERD (Erosive Esophagitis):**
* 1 year and older: 15-40 kg: 20 mg orally once daily; Greater than 40 kg: 40 mg orally once daily.
* Duration of treatment is typically 4-8 weeks.
* **Pathological Hypersecretory Conditions:** Safety and efficacy not established in pediatric patients.
## Dose Adjustments
* **Hepatic Impairment:** Maximum dose of 40 mg orally once daily.
* **Renal Impairment:** No dose adjustment is typically needed.
## Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
## Adverse Effects
Common adverse effects include headache, diarrhea, nausea, abdominal pain, and dizziness. Long-term use of PPIs may be associated with an increased risk of fractures (hip, wrist, spine), C. difficile infection, hypomagnesemia, and vitamin B12 deficiency.
## Key Drug Interactions
* **Drugs Dependent on Gastric pH for Absorption:** Pantoprazole can decrease the absorption of drugs like ketoconazole, itraconazole, and certain HIV protease inhibitors.
* **Methotrexate:** PPIs may increase methotrexate levels, potentially leading to toxicity.
* **CYP2C19 Substrates:** Pantoprazole is a moderate inhibitor of CYP2C19. Caution is advised with concomitant use of drugs primarily metabolized by this enzyme, although clinical significance is often unclear.
## Monitoring
* Monitor for signs and symptoms of hypomagnesemia (e.g., muscle cramps, seizures, tremors, arrhythmias), especially with prolonged use or concomitant use of other drugs that lower magnesium.
* Monitor for signs of C. difficile-associated diarrhea.
* Consider monitoring vitamin B12 levels with prolonged therapy.
## Clinical Pearls
* Administer oral pantoprazole 30 minutes to 1 hour before a meal.
* Intravenous administration can be given as a bolus injection or continuous infusion. Reconstitute and dilute according to manufacturer instructions.
* Long-term use should be periodically reassessed for appropriateness.
***
*This information is intended for healthcare professionals and does not replace current prescribing information. Always verify the most up-to-date drug information with official product labeling and relevant clinical guidelines.*
